Effective inhibition of cancer cells by recombinant adenovirus expressing EGFR-targeting artificial microRNA and reversed-caspase-3

Yan, Mengmeng; Chen, Jia; Jiang, Hua; Xie, Yuqiong; Li, Chunchun; Yang, Baoyu; Cao, Jiashu

doi:10.1371/journal.pone.0237098

Cited by 8 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This displayed a specific novel anti-cancer gene therapy strategy which combines EGFR inhibition as well as CASP3 induced apoptosis ( 130 , 131 ). The inhibitory effect caused by this adenovirus was commensurable to the therapeutic effects of cis-platinum and cetuximab ( 8 ).…”

Section: Most Common Cancers Treated With Gene Therapy: the Potentialmentioning

confidence: 99%

“…As discussed previously, suicide gene therapy is another interesting approach in cancer gene therapy. From this point of view, an expression vector was constructed from HSV1-tk and human interleukin-12 genes under transcriptional regulation of tumor-specific hSLPI (human secretory leukocyte protease inhibitor) promoter, which is known to be active in lung, breast, and ovary cancers ( 8 , 77 , 129 ). This vector displayed a more specific anti-tumor effect because of hSLPI promoter transcriptional regulation, besides demonstrating that suicide gene therapy combined with immune gene therapy provides a stronger anti-tumor effect than gene therapy using a single gene ( 77 ).…”

Section: Most Common Cancers Treated With Gene Therapy: the Potentialmentioning

confidence: 99%

“…Gene therapy consists in the introduction of therapeutic nucleic acids (TNAs) into target cells in order to achieve a beneficial molecular effect for patients. TNAs' delivery into cancer cells, such as genes, oligonucleotides, or interference RNAs, has enabled cancer battling by means of gene substitution, or genetic expression regulation either overexpression or repression (4)(5)(6)(7)(8). Notwithstanding, TNAs effect is transient and most of the time the desired effect has not been achieved.…”

Section: Introduction Cancer Basics and Available Treatments Why Usementioning

confidence: 99%

“…Cancer/tumor-specific promoters have been used to perform gene therapy in many types of neoplasia; within the most studied ones we have hepatocellular carcinoma, breast, lung, colorectal, pancreas and prostate cancer (8,(10)(11)(12)(13). Gene therapy success in cancer treatment relies not only on a good molecular strategy, which consists of the design of specific genetic material being exclusively expressed within tumor cells, but also on the need of a safe, efficient and specific gene delivery system.…”

Section: Introduction Cancer Basics and Available Treatments Why Usementioning

confidence: 99%

See 3 more Smart Citations

Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters

et al. 2020

View full text Add to dashboard Cite

Cancer is the second cause of death worldwide, surpassed only by cardiovascular diseases, due to the lack of early diagnosis, and high relapse rate after conventional therapies. Chemotherapy inhibits the rapid growth of cancer cells, but it also affects normal cells with fast proliferation rate. Therefore, it is imperative to develop other safe and more effective treatment strategies, such as gene therapy, in order to significantly improve the survival rate and life expectancy of patients with cancer. The aim of gene therapy is to transfect a therapeutic gene into the host cells to express itself and cause a beneficial biological effect. However, the efficacy of the proposed strategies has been insufficient for delivering the full potential of gene therapy in the clinic. The type of delivery vehicle (viral or non viral) chosen depends on the desired specificity of the gene therapy. The first gene therapy trials were performed with therapeutic genes driven by viral promoters such as the CMV promoter, which induces non-specific toxicity in normal cells and tissues, in addition to cancer cells. The use of tumor-specific promoters over-expressed in the tumor, induces specific expression of therapeutic genes in a given tumor, increasing their localized activity. Several cancer- and/or tumor-specific promoters systems have been developed to target cancer cells. This review aims to provide up-to-date information concerning targeting gene therapy with cancer- and/or tumor-specific promoters including cancer suppressor genes, suicide genes, anti-tumor angiogenesis, gene silencing, and gene-editing technology, as well as the type of delivery vehicle employed. Gene therapy can be used to complement traditional therapies to provide more effective treatments.

show abstract

Section: Most Common Cancers Treated With Gene Therapy: the Potentialmentioning

confidence: 99%

Section: Most Common Cancers Treated With Gene Therapy: the Potentialmentioning

confidence: 99%

Section: Introduction Cancer Basics and Available Treatments Why Usementioning

confidence: 99%

Section: Introduction Cancer Basics and Available Treatments Why Usementioning

confidence: 99%

See 2 more Smart Citations

Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Different strategies have been developed for MYC inhibition, such as adenovirus expressing antisense c- MYC ( Chen et al, 2001 ; Xie et al., 2009 ) or shRNA anti- MYC ( Li Y et al, 2013 ) leading to tumor inhibition in vivo and in vitro ( Table S1 ). Other targets involved in cell proliferation and survival employed in adenovirus gene therapy include survivin inhibition ( Fei et al, 2008 ; Shen et al, 2009 ), Ki-67 silencing ( Zheng et al, 2009 ; Liu J et al, 2012 ), and epidermal growth factor receptor (EGFR) expression ( Yan et al, 2020 ).…”

Section: Adenovirus In Cancer Gene Therapymentioning

confidence: 99%

The use of adenoviral vectors in gene therapy and vaccine approaches

et al. 2022

View full text Add to dashboard Cite

Adenovirus was first identified in the 1950s and since then this pathogenic group of viruses has been explored and transformed into a genetic transfer vehicle. Modification or deletion of few genes are necessary to transform it into a conditionally or non-replicative vector, creating a versatile tool capable of transducing different tissues and inducing high levels of transgene expression. In the early years of vector development, the application in monogenic diseases faced several hurdles, including short-term gene expression and even a fatality. On the other hand, an adenoviral delivery strategy for treatment of cancer was the first approved gene therapy product. There is an increasing interest in expressing transgenes with therapeutic potential targeting the cancer hallmarks, inhibiting metastasis, inducing cancer cell death or modulating the immune system to attack the tumor cells. Replicative adenovirus as vaccines may be even older and date to a few years of its discovery, application of non-replicative adenovirus for vaccination against different microorganisms has been investigated, but only recently, it demonstrated its full potential being one of the leading vaccination tools for COVID-19. This is not a new vector nor a new technology, but the result of decades of careful and intense work in this field.

show abstract

Applications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy

Kumar¹,

Das²,

Emdad³

et al. 2023

Advances in Cancer Research

View full text Add to dashboard Cite

Effective inhibition of cancer cells by recombinant adenovirus expressing EGFR-targeting artificial microRNA and reversed-caspase-3

Cited by 8 publications

References 25 publications

Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters

Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters

The use of adenoviral vectors in gene therapy and vaccine approaches

Applications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy

Contact Info

Product

Resources

About